China currently ranks number two in the world in the number of scientific papers published and is quickly catching up with the US; China started a $1.3 billion fund to encourage clusters of emerging industries; 
Novartis said India's weak IP practices prevented the company from building an R&D center there; Pfizer announced a cutback in R&D but its Shanghai R&D operation was not affected; JOINN Laboratories (????????????) is building a 1.2 million square foot CRO facility in anticipation of big pharma demand for outsourced R&D work; WuXi PharmaTech (????) signed a LOI for a new R&D facility; BMP Sunstone (???????????) will distrbute an endometriosis product for Pfizer in China; D-Pharm outlicensed the China rights for its stroke treatment to Wanbang Biopharma; Simcere Pharma (????) acquired a statin drug from Tianjin Tianda Pharma; Lijun International Pharma said its antiviral drug was effective against H1N1; China Medical Technologies (????????) received SFDA approval for a Leukemia FISH Probe; and five smaller biopharmas released positive earnings reports. More details... 

Stock symbols: (NYSE: NVS) (NYSE: PFE) (NYSE: WX) (NSDQ: BJGP) (TASE: DPRM) (NYSE: SCR) (HKEX: 2005) (NSDQ: CMED)

Biodel Inc. (Nasdaq:BIOD) announced Dr. Solomon Steiner, Chairman and CEO of Biodel, will present a corporate update at the Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009 at 9:40 am Atlantic Time.

AMRI (NASDAQ:AMRI) announced AMRI Director of Investor Relations Peter Jerome will present at the Oppenheimer 20th Annual Healthcare Conference in New York City on Tuesday, November 3, 2009 at 3:20 p.m. EST.

BioScrip, Inc. (Nasdaq:BIOS) announced third quarter net income of $5.7 million, or $0.14 per diluted share, on revenues of $333.5 million. These results compare to net income of $1.4 million, or $0.04 per share, on revenues of $359.4 million for the third quarter of 2008.

Celgene Corporation (NASDAQ:CELG) announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company.

ARYx Therapeutics, Inc. (NASDAQ:ARYX) announced it will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 10:15 am Eastern.

Javelin Pharmaceuticals, Inc. (NYSE:JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, received commitments from a single institutional investor, to purchase up to 3,186,700 shares of its common stock for estimated gross proceeds of approximately $3.9 million.

China-Biotics, Inc. (Nasdaq:CHBT), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, announced the appointment of Dr. Tom Gu as Vice President, effective November 2.

BMP Sunstone Corporation (Nasdaq:BJGP), announced it will participate in the following conferences: -- Oppenheimer 20th Annual Healthcare Conference, to be held November 3-4, 2009 at the Waldorf=Astoria hotel in New York.

Warner Chilcott plc (Nasdaq:WCRX) announced it has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business.

NeoStem, Inc. (NYSE:NBS), announced the Company has completed theacquisition of China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP), a leading Chinese pharmaceutical company.

Javelin Pharmaceuticals, Inc. (NYSE:JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, received commitments from a single institutional investor, to purchase up to 3,186,700 shares of its common stock for estimated gross proceeds of approximately $3.9 million.

BSD Medical Corporation (NASDAQ:BSDM) announced published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer.

Safeguard Scientifics, Inc. (NYSE:SFE), a holding company builds value in growth-stage life sciences and technology companies, announced it will release its financial results for the third quarter ended September 30, 2009 prior to market open on Wednesday, November 4, 2009.

Emergent Health Corp. (OTC:EMGE) Emergent (the “Company”) is pleased to announce a forward stock split of 11 shares for each 10 shares owned.

NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced it will hold a conference call on Friday, November 6, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its third quarter 2009.

Rosetta Genomics (NASDAQ:ROSG) announced Ayelet Chajut, its Executive Vice President, R&D, Head of Molecular Biology will speak at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI).

Shire plc (NASDAQ:SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

Valeant Pharmaceuticals International (NYSE:VRX) announced it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.

Impax Laboratories, Inc. (NASDAQ:IPXL) confirms it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICO® (fenofibrate) tablets, 48 mg and 145 mg.

PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, announced Michael J. Culota, Executive Vice President and Chief Financial Officer, will make a presentation regarding the Company at the Oppenheimer 20th Annual Healthcare Conference in New York City on Tuesday, November 3, 2009, at 10:50 a.m. Eastern Time.

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced it will report financial results for the third quarter ending September 30, 2009 on Wednesday, November 4, 2009, after the U.S. financial markets close.

Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced it is scheduled to make an investor presentation at the 20th Annual Oppenheimer Healthcare Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company's presentation on Tuesday, November 3, 2009, at 3:55 p.m. Eastern Time.

GTx, Inc. (NASDAQ:GTXI) announced it will host a conference call and webcast on Monday, November 2, 2009 to provide an update regarding the New Drug Application for toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy.

Talecris Biotherapeutics Holdings Corp. (Nasdaq:TLCR) will release its third quarter 2009 financial results on November 9, 2009, after the stock market closes, and will host a conference call at 8:30 AM Eastern Time on November 10, 2009.

Covidien (NYSE:COV), a leading global provider of healthcare products, announced its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII).

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced it will report financial results for the third quarter ending September 30, 2009 on Wednesday, November 4, 2009, after the U.S. financial markets close.

Novavax, Inc. (Nasdaq:NVAX) announced it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, November 6, 2009.

Geron Corporation (Nasdaq:GERN) announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based produc , GRNOPC1, for the treatment of spinal cord injury.

CVS Caremark (NYSE:CVS) announced the appointment of David M. Denton to the new role of Executive Vice President and Chief Financial Officer, effective January 1, 2010. Denton will succeed David Rickard who announced in February of this year his intention to retire as CFO.

NovaDel Pharma Inc. (NYSE:NVD), announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

NexMed, Inc. (Nasdaq:NEXM), a developer of innovative topical products based on the NexACT® technology, announced management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST.

IMS Health (NYSE:RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital (“TPG”) and the CPP Investment Board (“CPPIB”) in a transaction with a total value of $5.2 billion, including the assumption of debt.

StemCells, Inc. (NASDAQ:STEM) reported financial results for the third quarter ended September 30, 2009.

EpiCept Corporation (Nasdaq:EPCT) announced it will host a conference call to discuss third quarter 2009 operating and financial results on Tuesday, November 10, 2009 at 9:00 a.m. EST. The call will follow the release of these financial results earlier in the day at 12:01 a.m. EST.

BMP Sunstone Corporation (Nasdaq:BJGP) announced the Company plans to release third quarter 2009 financial results on Monday, November 9, 2009, after the market closes.

Transgenomic, Inc. (OTC:TBIO) announces the following Webcast:  What: Transgenomic, Inc. Third Quarter 2009 Earnings Release Conference Call When: Thursday, November 5, 2009 @ 5:00 p.m. Eastern.

Unilife Medical SolutionsLimited (OTC:UNIFF) wishes to advise shareholders of the release of a Finance News Network interview conducted recently with Unilife CEO Alan Shortall.

Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced its financial results for the third quarter ended September 30, 2009.

VIVUS, Inc. (Nasdaq:VVUS) announced Leland Wilson, chief executive officer, will present an overview of the company at Merriman Corhan Ford's 6th Annual Investor Summit.

MAP Pharmaceuticals, Inc. (Nasdaq:MAPP) announced financial results for the third quarter ended September 30, 2009.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford’s 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse’s 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November 12, 2009.

Levi & Korsinsky is investigating the Board of Directors of IMS Health Inc. (NYSE:RX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm TPG and the CPP Investment Board of Toronto ("CPP").

OncoVista Innovative Therapies, Inc. (OTC:OVIT) reported strong growth in revenue, in the second quarter of 2009.

CVS Caremark Corporation (NYSE:CVS) announced its Board of Directors has approved a new share repurchase program for up to $2.0 billion of its outstanding common stock.

Emergent BioSolutions Inc. (NYSE:EBS) announced its financial results for the third quarter and nine months ended September 30, 2009.

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, announced financial results for the quarter ended September 30, 2009.

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, reported its financial results for the third quarter ended September 30, 2009.

Life Sciences Research, Inc. (NYSE:LSR) announced financial results for the three and nine months ended September 30, 2009.

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, announced financial results for the third quarter ended September 30, 2009.

S3 Investment Company, Inc. (OTC:SIVC) issued comment from Chairman and CEO Jim Bickel regarding the recent progress of its wholly owned subsidiary businesses, Redwood Capital and Redwood Medical, both of which operate in the China market.

Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ® to include long-term data from the CASTLE Study.